ArticleBMC oral health2026
Changes in gingival cancer: burden of hospitalization and epidemiological evolution from 2001 to 2023 in Spain. a novel approach using hospital activity registry data.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGingival squamous cell carcinoma represents approximately 10% of oral cavity carcinomas. The Spanish Hospital Activity Registry (RAE) covers > 90% of the Spanish population and provides updated epidemiological data. This study aims to describe the epidemiological evolution of gingival cancer in Spain from 2001 to 2023 by analysing sex distribution, age groups, anatomical location (maxilla vs. mandible) and hospitalization costs.
methodsThis was a retrospective cohort study using RAE data from January 1, 2001, to December 31, 2023. We selected hospital admissions with primary or secondary diagnoses of gingival malignancy (ICD-9 code 143 and ICD-10 code C03), treatment, or regional spread related to the tumour. We selected only the first admission for each patient during the study period. Variables analysed: sex, age, location (maxilla/mandible), and economic cost adjusted to the 2023 Consumer Price Index.
resultsA total of 7,327 admissions were identified, corresponding to 5,623 patients. The number of cases increased from 198 in 2001 to 315 in 2023 (+ 59.1%). The male: female ratio shifted from 1.3:1 (2001) to 0.8:1 (2023), with a female predominance consolidated after 2015. The mean age at diagnosis was greater in women (71.1 years) than in men (65.3 years), p < 0.001. When the location was specified, 63% were mandibular, and 37% were maxillary. The mean cost per admission rose from €7,007 to €13,114. The total hospital cost increased from €1.67 million (2001) to €4.69 million (2023), representing a 180% increase.
conclusionsRAE is a valuable data source for monitoring cancer trends in Spain. Since 2015, there has been a sustained shift toward female predominance in the incidence of gingival cancer, with a greater diagnostic age in women. The economic burden of gingival cancer hospitalization has increased substantially, with both higher case numbers and increased costs per patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.